Bosentan and Ribociclib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Moderate CYP3A induction may reduce ribociclib exposure.
Clinical significance and safety
Bosentan with Ribociclib may reduce ribociclib effectiveness, particularly with lower ribociclib regimens. The current product information distinguishes moderate inducers from strong inducers rather than applying the strong-inducer avoidance rule indiscriminately. The prescriber should consider the actual regimen, possible alternatives and clinical response; do not alter doses yourself.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.